Larimar Therapeutics LRMR shares are trading lower after the company reported an FDA clinical hold on CTI-1601 clinical program and that the company will not be closing a previously announced private placement financing.
Larimar Therapeutics is currently down 32.02% to a price of $8.72. The stock's current volume for the day is 1.93 million, which is approximately 1092.43% of its previous 30-day average volume of 176.49 thousand.
The 50-day moving average price of Larimar Therapeutics's stock was $14.05 when this article was published. The stock reached a high of $25.87 and a low of $8.0 in the past 52 weeks.
Benzinga Pro provides investors with timely and accurate explanations of why a stock is moving. Subscribe to receive real-time alerts explaining stock price movements. Click here to learn more.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
